GLP1R and type 2 diabetes mellitus: Type 2 diabetes is a major global public health issue, with cardiovascular (CV) and kidney complications contributing to its disease burden.1,2 Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have emerged as an important therapeutic class, offering both glycemic control and potential cardioprotective and nephroprotective benefits.3,4,5 However, GLP-1 RAs are not a pharmacologically homogenous class, and their effects on specific CV outcomes appear to vary among agents and patient populations.